Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 3/20 | 0.40 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD4 | P21917 | 2/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19381939 | 0.87 | DRD3 (0.44) | DRD3DRD2DRD4CHRNA7KCNH2 | |
| SCHEMBL13263648 | 0.84 | DRD3 (0.47) | DRD3DRD2DRD4 | |
| SCHEMBL19368172 | 0.81 | DRD3 (0.42) | DRD3DRD2DRD4CHRNA7KCNH2 | |
| SCHEMBL13233305 | 0.80 | DRD3 (0.41) | DRD3DRD2DRD4CHRNA7KCNH2 | |
| SCHEMBL19852248 | 0.79 | DRD3 (0.46) | DRD3DRD2DRD4 | |
| SCHEMBL21072109 | 0.79 | DRD3 (0.46) | DRD3DRD2DRD4 | |
| SCHEMBL5858597 | 0.78 | DRD3 (0.50) | DRD3DRD2DRD4CHRNA7KCNH2 | |
| SCHEMBL20328234 | 0.77 | SIGMAR1 (0.51) | — | |
| SCHEMBL19381894 | 0.77 | CHRNA7 (0.58) | CHRNA7KCNH2MAPK1 | |
| SCHEMBL26235665 | 0.77 | CHRNA7 (0.58) | CHRNA7KCNH2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288409-B2 | Quinolizidinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288409-B2 | Quinolizidinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20100324024-A1 | Quinolizidinone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100324024-A1 | Quinolizidinone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2010-12-23 | — | — | US | disclosed |
| WO-2009102574-A1 | QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK & CO., INC. (US) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324024-A1 | Quinolizidinone M1 Receptor Positive Allosteric Modulators | CHRM1, CHRM2, OPRL1 | DRD3 394/4885MAP3K12 3323/4885DRD2 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.